Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer Profits Drop On Lower Covid-19 Product Sales

Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts.

International Business Times

Stock Index Futures Slip as Investors Await Fed Rate Decision, U.S. PMI and Jobs Data on Tap

June S&P 500 E-Mini futures (ESM24) are down -0.42%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.73% this morning as mixed earnings and the prospect of higher-for-longer U.S. interest rates weighed on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

Barchart

Stock Index Futures Slip as Fed Rate Decision Looms, U.S. Jobs Data on Tap

June S&P 500 E-Mini futures (ESM24) are down -0.29%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.58% this morning as the prospect of higher-for-longer U.S. interest rates continued to weigh on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Index Futures Slip as Investors Await Fed Rate Decision, U.S. Jobs Data on Tap

Barchart

Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure

The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.

Investors Business Daily

5 Underperforming Stocks That Look Ready to Rebound, According to Goldman

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

Barchart

Drugmakers' low U.S. taxes belie their high sales

Most of the largest pharmaceutical companies report losing money in the United States, despite the majority of their sales coming from Americans. The result is lower U.S. taxes for the companies.

WEKU

Read news from The Economist, FT, and more,
with one subscription

Most at-risk Aussies don't have COVID-19 plan with a GP

Some 75 per cent of Australians at higher risk of serious illness from COVID-19 do not have a plan to manage the potentially-lethal virus, new research shows.

AAP

2 Defensive Stocks to Buy Now as 'Higher For Longer' Woes Rattle Markets

U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.

Barchart

“WHERE ARE YOUR ETHICS?”: Lady Gaga Slammed For Promoting Migraine Med

"It's like you've become a complete[ly] different person," outraged fans said as they criticized Lady Gaga for the commercial for Pfizer's migraine medication. The post “WHERE ARE YOUR ETHICS?”: Lady Gaga Slammed For Promoting Migraine Med first appeared on Bored Panda.

Bored Panda

Down 32% in a Year, Should Investors Buy the Dip in Pfizer Stock?

Down more than 30% in a year, pharmaceutical company Pfizer trades near its 52-week lows. Is this the right time to buy in the dip?

Barchart

New mRNA therapy shows promise in treating 'ultrarare' inherited disease

Initial trial results suggest that a new mRNA therapy may be able to safely and effectively treat propionic acidemia, a rare metabolic disorder.

LiveScience

Manipal Hospitals collaborates with Pfizer to improve patient care

Manipal Hospitals partners with Pfizer to enhance adult vaccination program, focusing on preventing vaccine preventable diseases efficiently.

The Hindu

Cheaper private Covid jabs may end up as costly as pricier ones, say experts

Exclusive: Multi-dose vials could push up charge per patient, with experts warning cost could widen inequalities

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Cost of private Covid jabs risks widening health inequalities, experts warn

Concerns that some groups who are more at risk from virus face hefty price tag, as Boots set to charge almost £100 a shot

The Guardian - UK

Boots to offer Covid vaccines in England for nearly £100 a jab

Pharmacy to offer Pfizer/BioNTech vaccine to those not eligible for NHS booster shot from next week

Investors Business Daily

BioNTech Hits Three-Year Low As Covid Vaccine Sales Plummet 65%, Missing Forecasts

BioNTech stock tumbled Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit.

WEKU

In a pandemic milestone, the NIH ends guidance on COVID treatment

The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

COVID patients can't get Paxlovid

The price is one reason Paxlovid is not reaching those who need it most

The Texas Tribune

Why covid patients who could most benefit from paxlovid still aren’t getting it

During the pandemic, the federal government offered Americans a 5-day course of Paxlovid, the antiviral drug that lessens COVID-19 symptoms. But now that Pfizer is charging for it, confusion over insurance coverage, price, has made patients wary.

The Guardian - UK

Covid vaccines cut risk of virus-related heart failure and blood clots, study finds

Researchers say jabs substantially reduce for up to a year the chances of serious cardiovascular complications

Reason

Does Anonymity Defeat Associational Standing?

The Second Circuit divides over whether an association must identify an injured member by name for the purposes of Article III. (Updated)

Salon

U.S. must stop syphilis killing babies

The government isn’t doing much to prevent shortages of the only drug that treats syphilis during pregnancy

Barchart

Should You Buy These 2 Dividend Stocks Yielding More Than 5% Right Now?

There are other reasons to consider buying a dividend stock besides the high yield. Here's a closer look at two stocks that offer yields over 5% right now.

Investors Business Daily

BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug

Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. But BridgeBio stock tumbled Monday.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.